Known targets — ChEMBL curated mechanism
DRD1DRD2DRD3DRD4DRD5SLC6A2SLC6A4
The experimentally established mechanism targets of Amoxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 1.00 |
| ▸ | DRD5 known ✓ | P21918 | 2/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amoxapine SCHEMBL33950 | 1.00 | DRD2 (1.00) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL29482386 | 1.00 | DRD2 (1.00) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL5498936 | 1.00 | DRD2 (1.00) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL29370074 | 1.00 | DRD2 (1.00) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL29180215 | 0.99 | DRD2 (0.98) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL8741185 | 0.96 | DRD2 (0.93) | DRD2DRD4CHRM1DRD3HTR1A | |
| SCHEMBL2738976 | 0.90 | DRD4 (0.82) | DRD2DRD4CHRM1DRD3HTR1A | |
| SCHEMBL3409689 | 0.89 | DRD2 (0.80) | DRD2DRD4CHRM1DRD3HTR1A | |
| SCHEMBL25410757 | 0.87 | HRH4 (0.77) | DRD2DRD4CHRM1DRD3HTR1A | |
| Amoxapine SCHEMBL21225243 | 0.87 | DRD2 (0.76) | DRD2DRD4CHRM1DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| EP-3529229-B1 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | SYNEURX INT TAIWAN CORP (TW) | 2024-04-17 | — | — | EP | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2023064228-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |
| US-12550235-B2 | — | — | 2026-02-10 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| CN-114702454-A | Preparation method of 5-alkyl-11-aryl-5H-dibenzo [ b, e ] [1,4] diazepine derivative | 江西师范大学 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022104059-A1 | RAPIDLY INFUSING COMPOSITIONS AND METHODS | Orcosa Inc. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3979865-A1 | MICROWAVE HEATING UNIT AND METHOD | NVX Labs GmbH (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3747289-B1 | MICROWAVE HEATING UNIT AND METHOD | NVX LABS GMBH (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | DRD2 6/4885DRD4 39/4885DRD3 22/4885 |
| US-12550235-B2 | — | MTX2, CRY2, MTX1 | DRD2 4116/4885DRD4 4554/4885DRD3 4336/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885DRD4 4407/4885DRD3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.